文献速递脑血管病

活动性癌症合并缺血性卒中患者血管内治疗后的临床结局:MR CLEAN登记研究子研究

Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR CLEAN Registry Substudy.
PubMed 文献 · Neurology · 2022-01-11

基于MR CLEAN登记研究,比较活动性癌症合并急性缺血性卒中患者与无癌症患者接受血管内治疗后的临床与安全结局。活动性癌症患者90天功能结局更差(acOR 2.2,95%CI 1.5-3.2),死亡风险更高(aOR 3.2,95%CI 2.1-4.9),复发卒中更多(aOR 3.1,95%CI 1.2-8.1),但成功再灌注和症状性颅内出血率无差异。

要点

  • 活动性癌症患者血管内治疗后90天功能结局更差,死亡风险更高。
  • 活动性癌症患者90天内复发卒中风险增加,但症状性颅内出血率无差异。
  • 约四分之一活动性癌症患者仍获得功能独立。

核心结论

  • 尽管技术成功率相似,活动性癌症患者急性缺血性卒中血管内治疗后结局显著更差,且复发卒中风险增加。
  • 约四分之一患者仍获得功能独立,其他并发症(尤其是症状性颅内出血)风险未增加。

研究设计与样本

  • 基于荷兰MR CLEAN登记研究数据,比较活动性癌症患者(卒中前12个月内诊断癌症、转移性疾病或正在接受癌症治疗)与无癌症患者。
  • 共2583例接受血管内治疗的患者,其中124例(4.8%)有活动性癌症。
  • 对预后变量进行调整分析,并在卒中前mRS评分为0或1的患者中及按治疗设置(根治性或姑息性)进行亚组分析。

主要发现

  • 活动性癌症患者卒中前残疾更常见(mRS评分≥2:34.1% vs 16.6%)。
  • 90天功能结局向更差方向偏移(acOR 2.2,95%CI 1.5-3.2)。
  • 90天时活动性癌症患者独立比例更低(mRS评分0-2:22.6% vs 42.0%,aOR 0.5,95%CI 0.3-0.8),死亡比例更高(52.2% vs 26.5%,aOR 3.2,95%CI 2.1-4.9)。
  • 成功再灌注(67.8% vs 60.5%,aOR 1.4,95%CI 1.0-2.1)和症状性颅内出血率(6.5% vs 5.9%,aOR 1.1,95%CI 0.5-2.3)无差异。
  • 90天内复发卒中在活动性癌症患者中更常见(4.0% vs 1.3%,aOR 3.1,95%CI 1.2-8.1)。

关键数值与推荐

  • 活动性癌症定义为卒中前12个月内诊断癌症、转移性疾病或正在接受癌症治疗。
  • 成功再灌注定义为扩展脑梗死溶栓评分≥2b。
  • 本研究提供I级证据表明活动性癌症患者接受血管内治疗后90天功能结局较无活动性癌症患者更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To explore clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment (EVT). METHODS: Using data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, we compared patients with active cancer (defined as cancer diagnosed within 12 months before stroke, metastatic disease, or current cancer treatment) to patients without cancer. Outcomes were 90-day modified Rankin Scale (mRS) score, mortality, successful reperfusion (expanded Treatment in Cerebral Infarction score ≥2b), symptomatic intracranial hemorrhage (sICH), and recurrent stroke. Subgroup analyses were performed in patients with a prestroke mRS score of 0 or 1 and according to treatment setting (curative or palliative). Analyses were adjusted for prognostic variables. RESULTS: Of 2,583 patients who underwent EVT, 124 (4.8%) had active cancer. They more often had prestroke disability (mRS score ≥2: 34.1% vs 16.6%). The treatment setting was palliative in 25.3% of the patients. There was a shift toward worse functional outcome at 90 days in patients with active cancer (adjusted common odds ratio [acOR] 2.2, 95% confidence interval [CI] 1.5-3.2). At 90 days, patients with active cancer were less often independent (mRS score 0-2: 22.6% vs 42.0%, adjusted OR [aOR] 0.5, 95% CI 0.3-0.8) and more often dead (52.2% vs 26.5%, aOR 3.2, 95% CI 2.1-4.9). Successful reperfusion (67.8% vs 60.5%, aOR 1.4, 95% CI 1.0-2.1) and sICH rates (6.5% vs 5.9%, aOR 1.1, 95% CI 0.5-2.3) did not differ. Recurrent stroke within 90 days was more common in patients with active cancer (4.0% vs 1.3%, aOR 3.1, 95% CI 1.2-8.1). The sensitivity analysis of patients with a prestroke mRS score of 0 or 1 showed that patients with active cancer still had a worse outcome at 90 days (acOR 1.9, 95% CI 1.2-3.0). Patients with active cancer in a palliative treatment setting regained functional independence less often compared to patients in a curative setting (18.2% vs 32.1%), and mortality was higher (81.8% vs 39.3%). DISCUSSION: Despite similar technical success, patients with active cancer had significantly worse outcomes after EVT for AIS. Moreover, they had an increased risk of recurrent stroke. Nevertheless, about a quarter of the patients regained functional independence, and the risk of other complications, most notably sICH, was not increased. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that patients with active cancer undergoing EVT for AIS have worse functional outcomes at 90 days compared to those without active cancer.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Verschoof MA, Groot AE, de Bruijn SFTM, et al. Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR CLEAN Registry Substudy. Neurology. 2022. PMID: 35017306. doi:10.1212/WNL.0000000000013316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。